In vitro model to simulate multiple drugs with distinct elimination half-lives

Area of Science:

• Pharmacology and Microbiology
• Drug Development and Discovery
• In Vitro Modeling

Background:

• Rising drug resistance in pathogens such as HIV and bacteria necessitates combination therapies.
• Combination therapies often involve agents with varying human elimination half-lives.
• Existing in vitro models struggle to realistically simulate diverse pharmacokinetic profiles.

Purpose of the Study:

• To develop and validate an in vitro hollow-fibre system capable of simulating multiple distinct drug elimination half-lives.
• To create a model that accurately reflects in vivo pharmacokinetic conditions for combination therapy evaluation.
• To provide a tool for guiding early-stage drug development in combination therapies.

Main Methods:

• Simulated four distinct pharmacokinetic profiles with elimination half-lives of 1, 2.5, 8, and 12 hours using ceftriaxone.
• Employed a parallel experimental setup with supplemental reservoirs to manage drug elimination.
• Achieved target drug concentrations and characterized pharmacokinetic parameters via serial sampling and spectrophotometric assay.

Main Results:

• Observed drug maximum concentrations closely matched mathematical predictions.
• Experimentally determined elimination half-lives were in agreement with simulated values.
• The system successfully replicated the intended pharmacokinetic profiles.

Conclusions:

• The developed in vitro system effectively simulates multiple pharmacokinetic profiles for combination therapy assessment.
• This adaptable framework can evaluate up to four-drug combinations against multidrug-resistant bacteria or HIV.
• The system represents a valuable tool for advancing combination therapy research and development.